BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...sclerosis (ALS). In early December, Biohaven Pharmaceutical Co. Ltd. (NYSE:BHVN) said the glutamate modulator troriluzole (BHV-4157...
BioCentury | Dec 7, 2019
Company News

Dec. 6 Company Quick Takes: Alexion rebuffs activist’s push for sale; plus UCB, Genmab, Enzyvant, Biohaven

...Ltd. (NYSE:BHVN) said it will continue its Phase II/III T2 Protect AD trial of troriluzole (BHV-4157...
BioCentury | Oct 6, 2017
Clinical News

Biohaven's trigriluzole misses in Phase IIb/III

...Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) reported top-line data showing that trigriluzole (BHV-4157) missed the primary...
...plans to start a Phase II/III trial of trigriluzole to treat obsessive compulsive disorder (OCD). Trigriluzole...
...a glutamate modulating agent. Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN), New Haven, Conn. Product: Trigriluzole (BHV-4157...
BioCentury | Oct 2, 2017
Clinical News

Biohaven falls on trigriluzole miss

...Holding Co. Ltd. (NYSE:BHVN) lost $1.82 to $35.56 on Monday after reporting that trigriluzole ( BHV-4157...
...treat spinocerebellar ataxia. CEO Vlad Coric told BioCentury the company will determine next steps for trigriluzole...
...compulsive disorder (OCD). Trigriluzole is a prodrug formulation of riluzole, a glutamate modulating agent. Elizabeth S. Eaton riluzole trigriluzole Biohaven...
BioCentury | Jun 2, 2017
Clinical News

Biohaven completes enrollment in Phase IIb/III of trigriluzole for spinocerebellar ataxia

...with hereditary spinocerebellar ataxia in a Phase IIb/III trial evaluating once-daily 140 mg oral trigriluzole (BHV-4157...
...walk, Sheehan Disability Scale, Patient and Clinician Global Impression of Change scales, safety and pharmacokinetics. Trigriluzole...
...U.S. for spinocerebellar ataxia. Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN), New Haven, Conn. Product: Trigriluzole (BHV-4157...
BioCentury | May 4, 2017
Financial News

Biohaven raises $168.3M in bumped-up IPO

...valued at $490 million. Biohaven expects data in 1Q18 from a Phase II/III trial of trigriluzole...
...CGRP) antagonist, to treat migraine. It expects data from those studies in 1Q18 as well. Chris Lieu rimegepant trigriluzole Biohaven...
BioCentury | Apr 10, 2017
Financial News

Biohaven planning $100M IPO

...William Blair and Needham. In December, Biohaven began a Phase II/III study of trigriluzole (formerly BHV-4157...
...is a prodrug formulation of riluzole, a glutamate modulating agent. Biohaven obtained worldwide rights to trigriluzole...
...has raised more than $100 million in private funding (see BioCentury, Nov. 4, 2016) . Paul Bonanos BHV-4157 BMS-927711 Biohaven...
BioCentury | Dec 30, 2016
Clinical News

BHV-4157: Ph IIb/III started

...BHV-4157 in about 120 patients. Biohaven Pharmaceutical Holding Co. Ltd. , New Haven, Conn. Product: BHV-4157...
...time of the 8 meter walk, safety and pharmacokinetics Status: Phase IIb/III started Milestone: NA Julian Zhu BHV-4157 Biohaven...
BioCentury | Nov 5, 2016
Finance

Craving Biohaven

...and “some very interesting high-value Orphan drugs in CNS.” Of particular interest for Aisling was BHV-4157...
...pivotal data out in a couple of indications.” Coric said Biohaven also plans to study BHV-4157...
BioCentury | Nov 1, 2016
Financial News

Biohaven raises $80M round

...agents. Biohaven has said it hopes to start a Phase III study by 1Q17 of BHV-4157...
...spinocerebellar ataxia. The compound has Orphan Drug designation in the U.S. in the indication. Jaime De Leon BHV-0223 BHV-4157 Biohaven...
Items per page:
1 - 10 of 10